Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,873 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
Narazaki M, Tanaka T, Kishimoto T. Narazaki M, et al. Among authors: kishimoto t. Expert Rev Clin Immunol. 2017 Jun;13(6):535-551. doi: 10.1080/1744666X.2017.1295850. Epub 2017 Mar 3. Expert Rev Clin Immunol. 2017. PMID: 28494214 Review.
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, Arimitsu J, Narazaki M, Hagihara K, Ogata A, Katayama I, Kawase I, Kishimoto T, Tanaka T. Shima Y, et al. Among authors: kishimoto t. Rheumatology (Oxford). 2010 Dec;49(12):2408-12. doi: 10.1093/rheumatology/keq275. Epub 2010 Sep 5. Rheumatology (Oxford). 2010. PMID: 20819796 Free PMC article.
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: kishimoto t. J Rheumatol. 2014 Apr;41(4):759-67. doi: 10.3899/jrheum.130690. Epub 2014 Mar 15. J Rheumatol. 2014. PMID: 24634205 Clinical Trial.
Tocilizumab for the treatment of patients with refractory Takayasu arteritis.
Nakaoka Y, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, Yasui T, Ikeoka K, Ohtani T, Sakata Y, Shima Y, Kumanogoh A, Yamauchi-Takihara K, Tanaka T, Kishimoto T, Komuro I. Nakaoka Y, et al. Among authors: kishimoto t. Int Heart J. 2013;54(6):405-11. doi: 10.1536/ihj.54.405. Int Heart J. 2013. PMID: 24309452
Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, Nishimoto N, Kishimoto T. Imagawa T, et al. Among authors: kishimoto t. Mod Rheumatol. 2012 Feb;22(1):109-15. doi: 10.1007/s10165-011-0481-0. Epub 2011 Jun 12. Mod Rheumatol. 2012. PMID: 21667343 Clinical Trial.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Nishimoto N, et al. Among authors: kishimoto t. Mod Rheumatol. 2009;19(1):12-9. doi: 10.1007/s10165-008-0125-1. Epub 2008 Nov 1. Mod Rheumatol. 2009. PMID: 18979150 Free PMC article. Clinical Trial.
2,873 results